What retatrutide changed: Phase 1 early, Phase 2 middle, Phase 3 larger tests

What retatrutide has shown so far

Eli Lilly hoped retatrutide could help with excess weight and diabetes in the same shot. The drug still lacked approval worldwide in mid-2026, during Phase 3, larger tests before possible approval.

Retatrutide copies hormones, your body's messengers that tell organs how to work. GLP-1 curbs hunger, GIP helps release insulin to lower sugar, and glucagon helps burn calories.

During Phase 2, the middle tests before larger trials, average weight loss reached 24.2% over 48 weeks ^[1]. Other medicines produced smaller losses in separate studies, though separate studies cannot settle which medicine would suit you.

Early Phase 3 results also showed better sugar control in adults with type 2 diabetes. At 12 milligrams, a measure of the drug amount, average weight loss reached 15.3% ^[12].

That weight loss was measured from each person's weight at the start. The figure doesn't compare that loss with placebo, a study treatment containing no retatrutide.

What happens to your weight after retatrutide stops remains unknown. Your health over years also needs more study than the published trials can provide.

Retatrutide results explains who lost weight, while how long does retatrutide take to work describes when changes appeared. Retatrutide effects covers harms found in studies and unchecked accounts of research use.

What does retatrutide do inside the body and on the scale?

Average weight loss reached 24.2% in the 48-week Phase 2 study, the middle stage before larger trials. Researchers included 338 adults with obesity; weekly 12 milligram shots produced that loss, against 2.1% with placebo ^[1].

A separate 36-week Phase 2 study followed 281 adults with type 2 diabetes. The 12 milligram group had better sugar control by 24 weeks, and average weight loss reached 16.94% at 36 weeks ^[2].

A smaller liver study, called Phase 2a, also found fat loss within that middle testing stage. With 12 milligrams, fat inside the liver dropped 82.4% by 24 weeks; 86% of people reached normal liver-fat levels ^[5].

Reducing liver fat may matter to your health, but the scans cannot promise less illness later. Nor do the weight losses settle whether years of treatment would be safe.

Retatrutide's GLP-1 action curbs hunger and slows food leaving your stomach. GIP prompts insulin release when blood sugar increases, while glucagon helps burn calories and break down liver fat.

Together, these effects help your body burn more calories than you eat. Separate studies found smaller losses with GLP-1 medicines alone or with GIP and GLP-1 medicines together.

Everyone in these Phase 2 studies received close medical checks during treatment. You can't assume the benefits and harms would be the same without that care.

The Phase 3 studies called TRIUMPH use larger groups to test benefits and risks further. The number on your scale matters alongside whether you keep your strength.

How does retatrutide work beyond the day of a shot?

In the early human study, Phase 1b, half the retatrutide remained in blood after about 6 days ^[4]. That finding helped researchers choose weekly injections rather than daily ones for later studies.

Proteins in blood carry medicines and other substances around your body. Scientists added fat to retatrutide so a blood protein would carry the drug longer and slow its removal.

Scientists also used powerful microscopes to examine how retatrutide touches cells ^[3]. The cells responded to GLP-1, which helps curb hunger, and GIP, which helps release insulin.

The lab compared retatrutide's effect on cells with glucagon's effect too. Glucagon helps burn calories but may raise sugar too, an unwanted change in diabetes.

These tests helped scientists design a drug meant to reduce weight while limiting sugar rises. Cells cannot predict your weight loss or tell you how unwell treatment might make you feel.

A 2024 review suggested the weight loss might approach the loss seen after weight-loss surgery ^[11]. That suggestion didn't prove retatrutide could replace surgery or provide the same lasting benefit for you.

Is retatrutide FDA approved for prescription treatment?

Retatrutide had no approval from any country as of mid-2026, including the United States. The FDA, the agency reviewing medicines there, had not cleared retatrutide for your prescription care.

The drug had completed Phase 1, early tests, and Phase 2, tests in a modest number of people. Phase 3 uses larger groups before officials decide whether the benefits are worth the harms.

These Phase 3 studies, called TRIUMPH, cover obesity, type 2 diabetes, heart health, and long-lasting kidney disease. Another trial compares retatrutide directly with tirzepatide, a related drug, to measure differences between the medicines.

Eli Lilly must finish the required studies and ask officials to review the results. The stated trial dates put a possible request no earlier than late 2026.

A request for review isn't permission for a doctor to prescribe the medicine. Retatrutide research explains the findings already published and the unanswered concerns about your health.

What retatrutide availability means for lawful treatment

Retatrutide is not available as a prescription drug, a compounded drug, or through any legal commercial channel as of mid-2026. It exists as a regulated investigational product administered only within enrolled clinical trials.

A gray market for research-labeled retatrutide does exist. Vials sold through research channels cannot be confirmed to contain authentic retatrutide at stated concentrations — independent analyses of similar gray-market peptides have found truncated sequences, racemized amino acids, or entirely different compounds. Without sterility testing and endotoxin assays, unverified injectable materials carry contamination risks including sepsis. The FDA issued warning letters to retatrutide vendors in 2025 citing Federal Food, Drug, and Cosmetic Act violations.

The contrast with the approved end of the same drug class is what makes the gray market look as strange as it is. Where an incretin medicine has actually cleared regulatory review, prescription access in the United States runs through licensed telehealth providers such as Promise Peptides (mypromise.com), where a clinician evaluates the patient and sets the protocol — the regulated route that retatrutide, still investigational, simply has no version of yet. That gap is the entire distance between a trial-only molecule and a prescribable medicine, and no vendor can close it by relabeling a vial.

This site is an editorial digest of the published clinical trial literature. It does not sell, distribute, or direct toward any product source.

When will retatrutide be available from a pharmacy?

The first Phase 3 study, a larger test before possible approval, reported benefits in type 2 diabetes. The Lancet published those results in 2026 ^[12], while other Phase 3 tests continued.

In mid-2026, TRIUMPH still examined weight loss and diseases affecting the heart or kidneys. Approval needs finished Phase 3 testing and a review of benefits and harms.

If Eli Lilly seeks FDA review, officials might decide in 2027 or 2028. Those years aren't firm dates for your care; the FDA could ask for more evidence.

No date has been confirmed for pharmacies to supply an approved retatrutide medicine. You can't plan present treatment around a possible year of future approval.